SGMO
Interesante empresa con resultados de fase II alentadores para el SIDA, a buen precio y que ha caído un 25% en la última semana. Habría que echarle un ojo. Se habla de que la caída puede ser por posible entrada de instituciones o porque se auguran unos datos trimestrales malos que se presentarán el 8 de mayo.
Datos clínicos:
phase 2 study of SB-728-T, which the company believes may be a "functional cure" for HIV/AIDS. SB-728-T modifies the CCR5 gene, which produces the CCR5 protein, the main co-receptor employed by HIV to infect and kill CD4+ T cells, which play a principal role in immunity.
In early March, the company presented new data from a phase 1 study showing that a single treatment with SB-728-T produces a "durable reconstitution of the immune system" by expanding memory CD4+ T cells, which have the capacity to recall and then rapidly respond against HIV and other foreign antigens. The increase in CD4+ T cells appears to be both an immediate and long-term phenomenon. In an age where personalized medicine and associated biomarkers have gained credibility with regulators, data from this study also demonstrate that specific cell surface markers, as well as gene expression characteristics, might predict which patients would be most responsive to SB-728-T.
«Después de nada, o después de todo/ supe que todo no era más que nada.»